Skip to main navigation Skip to search Skip to main content

Mortality rates of patients treated with drotrecogin alfa for severe sepsis based on PROWESS eligibility

Research output: Contribution to journalMeeting abstractpeer-review

Original languageAmerican English
JournalDefault journal
StatePublished - Jan 1 2007

Disciplines

  • Pharmacy and Pharmaceutical Sciences

Cite this